Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

NCT02967679 is registered in ClinicalTrials.gov with MedDay Pharmaceuticals SA as lead sponsor.

NCT NCT02967679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02967679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Lead sponsor
MedDay Pharmaceuticals SA
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2016
Completion date
March 18, 2019
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-mag neuropathy, charcot-marie-tooth disease, charcot-marie-tooth disease type 1a, charcot-marie-tooth disease, type 1b, chronic inflammatory demyelinating polyneuropathy, peripheral neuropathy